Roguska, M.A., Pedersen, J.T., Henry, A.H., Searle, S.M.J., Roja, D.M., Avery, B., Hoffee, M., Cook, S., Lambert, J.M., Blattler, W.A., Rees, A.R. and Guild, B.C.
"A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing"
Prot. Engng. (1996) 9:895-904.
Roguska, M.A., Pedersen, J.T., Keddy, C.A., Henry, A.H., Searle, S.J., Lamber, J.M., Goldmacher, V.S., Blattler, W.A., Rees, A.R. and Guild, B.C. "Humanization of murine monoclonal antibodies through variable domain resurfacing" Proc. Natl. Acad. Sci. (1994) 91:969-973.
(see also mAb anti-B4).
|Acceptor Antibody:||Human IgG1 | k|
|Antigen:||CD56 (anti-NCAM (cell adhesion molecule)) antigen on human natural killer cells|
|Laboratory:||ImmunoGen, MA; University Bath, UK|
|Design:||Models of mouse and humanised V regions generated by AbM. Analyse FR residues within 5A of a CDR for changes in size, charge, hydrophobicity or potential to form H-bonds that could disturb the CDR conformation.|
|Frameworks:||VH G36005 | VL KV2F|
|CDRs:||All 6 VH and VL, Kabat Definition except that CDR-H2 was 7 residues shorter at the C-terminus.|
|Binding:||Binding to SW-2 cells was "indistinguishable" from mouse mAb using competition binding assays and indirect immunofluorescence binding assays (FACScan).|
|Expression:||transient expression in cos cells|
|Comment:||This mAb was also resurfaced.|
|Clinical Indication:||Small cell lung cancer|
|José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.|